Wall Street Money Is Leaving Just As Atrium's (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts.
Atrium Therapeutics Inc. (RNA)
Market is closed
Sector: Pharmaceutical Preparations
News See All
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc.
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025.
15 Stocks with the Biggest Hedge Fund Momentum
In this article, we talk about the 15 stocks with the biggest hedge fund momentum.
Avidity Biosciences, Inc. (RNA): A Bull Case Theory
We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA.
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
We recently published 10 Stocks With Easy 20-40% Gains. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the last week's best-performing stocks.
Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis
We recently published 10 Big Names Crushing Wall Street. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the top-performing stocks on Monday.
What Makes Avidity Biosciences (RNA) an Investment Choice?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
11 Best Performing Long Term Stocks According to Analysts
In this article, we will look at the 11 Best Performing Long Term Stocks According to Analysts.
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating
We recently published 10 Stocks with Surprising Gains. Avidity Biosciences Inc. (NASDAQ:RNA) is one of the best performers on Friday.
Hedge Fund Resource Center